Alkermes Investigational Site

Dayton, Ohio 45432

0 studies enrolling now · 14 studies all time

What they study most

Alcohol Use Disorder, Bipolar I Disorder, Major Depressive Disorder, Multiple Sclerosis, Opioid-induced Constipation, Relapsing Remitting Multiple Sclerosis, Schizophrenia, Schizophreniform Disorder

Studies at this site

• Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 — Completed
• A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 — Completed
• A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder — Completed
• A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia — Completed
• A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 — Completed
• A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study) — Completed
• A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD) — Completed
• A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study — Completed
• A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia — Completed
• A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD) — Completed
• A Long-Term Safety Study of ALKS 5461 — Completed
• A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study) — Completed
• A Phase 1 Safety Study in Adults With Schizophrenia — Completed
• ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC) — Completed